ARMSTRONG, A. W.; LEBWOHL, M.; BAGEL, J.; SCHLESINGER, T.; BANERJEE, S.; KISA, R. M.; SCHARNITZ, T.; HOYT, K.; STROBER, B. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s120, 2023. DOI: 10.25251/skin.7.supp.120. Disponível em: https://jofskin.org/index.php/skin/article/view/1959. Acesso em: 3 jul. 2024.